Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer4 Nov 2026

556 A phase I first-in-human trial of IL-12 genetically engineered myeloid cells in participants with relapsed, refractory solid tumors

Steven Highfill¹
Sabina Kaczanowska²
Jessica Lake³
Hong Lei³
James L Gulley³
Scott M Norberg⁴
Rosandra N Kaplan³

4 affiliations

¹1National Institutes of Health, Bethesda, MD, USA
²Pediatric Oncology Branch, Center for Cancer Research, Bethesda, Maryland, USA
³National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
⁴Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Open at source DOI Cite

Efficacy and specific toxicity profiles of GPRC5D- versus BCMA-targeted bispecific antibodies in relapsed/refractory multiple myeloma: a meta-analysis of clinical trials and real-world studies
Jiahao Ji, Xinyu Zhao, Bin Wang +2
Frontiers in immunology16 Oct 2026Peer-reviewedCC BYFull textImmunologyEurope PMC
A genetically engineered Citrobacter sp. XT1-2-2 modulates rhizosphere soil microbiome and induces root proteomic changes to reduce cadmium uptake in rice
Zhudong Liu, Dongxia Du, Wei Cheng +6
BMC Genomics19 Oct 2026Peer-reviewedCC BY-NC-ND 4.0Plant biologyCrossref
Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma
Esther Hazane Leroyer, Caroline Ziegler, Charline Moulin +5
Journal of Clinical Medicine4 Sep 2026Peer-reviewedCC BY 4.0Full text7 citedImmunology OncologyHAL
BCMA Targeted Therapies and Their Impact on Outcomes in Relapsed or Refractory Multiple Myeloma: Results From the French EMMY Cohort
Titouan Cazaubiel, Olivier Decaux, Aurore Perrot +21
European Journal of Haematology8 Oct 2026Peer-reviewedCC BY 4.0Full textGeneral biology OncologyHAL
Case Report: Anti-CD7 CAR-T cell therapy in two patients with relapsed/refractory acute leukemia of ambiguous lineage with aberrant CD7 expression
Shuai Zhang, Yuehui Lin
Frontiers in Immunology29 Oct 2026Peer-reviewedCC BY 4.0ImmunologyCrossref

Cite

BibTeX RIS

BibTeX

@article{highfill2026phase,
  title = {{556 A phase I first-in-human trial of IL-12 genetically engineered myeloid cells in participants with relapsed, refractory solid tumors}},
  author = {Steven Highfill and Sabina Kaczanowska and Jessica Lake and Hong Lei and James L Gulley and Scott M Norberg and Rosandra N Kaplan},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0556},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0556},
  note = {CC BY},
}

RIS

TY  - JOUR
TI  - 556 A phase I first-in-human trial of IL-12 genetically engineered myeloid cells in participants with relapsed, refractory solid tumors
AU  - Steven Highfill
AU  - Sabina Kaczanowska
AU  - Jessica Lake
AU  - Hong Lei
AU  - James L Gulley
AU  - Scott M Norberg
AU  - Rosandra N Kaplan
PY  - 2026
DA  - 2026/11/04
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0556
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0556
SN  - 2051-1426
ER  -

Related

Cite